Differences in Sirtuin Regulation in Response to Calorie Restriction in Cryptococcus neoformans

Area of Science:

• Mycology
• Molecular Biology
• Genetics

Background:

• Cryptococcus neoformans replicates in low glucose, a condition affecting lifespan.
• SIR2 (silent information regulator 2) regulates longevity in fungi, but its role in C. neoformans under nutrient restriction is unclear.
• Calorie restriction impacts fungal lifespan and antifungal sensitivity, with potential therapeutic implications.

Purpose of the Study:

• To investigate the role of SIR2 and calorie restriction in the lifespan of different Cryptococcus neoformans serotypes.
• To compare the molecular mechanisms underlying lifespan regulation in response to glucose starvation between serotype A (H99) and serotype D (RC2) strains.
• To assess the impact of SIR2 modulation and specific drugs on C. neoformans survival and antifungal sensitivity in vitro and in vivo.

Main Methods:

• Lifespan analysis of C. neoformans strains (H99 and RC2) under low glucose conditions.
• Transcriptome comparison between H99 and RC2 under calorie restriction.
• Real-time PCR to confirm gene expression levels of SIR2, TOR1, SCH9, and PKA1.
• Generation and analysis of RC2-sir2Δ mutant cells.
• Assessment of drug efficacy and infection models.

Main Results:

• 37.5% of C. neoformans strains exhibited pro-longevity under low glucose; serotype D strain RC2 showed a shortened lifespan.
• Gene expression analysis revealed differential regulation of SIR2, TOR1, SCH9, and PKA1 between H99 and RC2 under calorie restriction.
• While SIR2 deletion shortened RC2 lifespan, calorie restriction-induced lifespan shortening was SIR2-independent.
• SIR2-specific drugs modulated H99 lifespan but not RC2 lifespan or infection outcome, unlike in H99.

Conclusions:

• SIR2 regulation and response to calorie restriction are variable across C. neoformans serotypes.
• Strain-specific differences in SIR2 function and response to nutrient restriction exist within C. neoformans.
• Sirtuins' potential as therapeutic targets for fungal infections requires consideration of strain-specific variations in C. neoformans.